OBJECTIVE: To evaluate the impact of biphosphonate administration on subsequent (153)Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) uptake in bone metastases of patients with castration-resistant prostate cancer. PATIENTS AND METHODS: The bone uptake of (153)Sm-EDTMP was assessed in 40 consecutive patients with castration-resistant prostate cancer and multiple painful bone metastases and no prior bisphosphonate therapy. (153)Sm-EDTMP was repeated after 3 months in the presence of bisphosphonates (zoledronic acid every 4 weeks, first administration 1 week after (153)Sm-EDTMP administration). The retained activity in bone was evaluated 20 h after application using whole-body scintigraphy (acquisition 15 cm/min). RESULTS: Mean patient age was 69 ± 4.8 years (range 57-77 years). Mean PSA level at study entry was 18.2 ± 21.0 ng/ml. (153)Sm-EDTMP uptake ranged from 36.3 to 75.3% (mean 55.1 ± 10.9%) before bisphosphonate administration and 35.6 to 73.3% (mean 55.2 ± 10.4%) after bisphosphonate administration. No significant intra-individual difference with or without bisphosphonate treatment was observed (P = 0.647). CONCLUSIONS: Bisphosphonate treatment does not affect (153)Sm-EDTMP bone uptake in patients with castration-resistant metastatic prostate cancer. Thus, bisphosphonate treatment can be continued safely during samarium therapy.
OBJECTIVE: To evaluate the impact of biphosphonate administration on subsequent (153)Samarium-ethylene-diamine-tetramethyl-phosphonate (EDTMP) uptake in bone metastases of patients with castration-resistant prostate cancer. PATIENTS AND METHODS: The bone uptake of (153)Sm-EDTMP was assessed in 40 consecutive patients with castration-resistant prostate cancer and multiple painful bone metastases and no prior bisphosphonate therapy. (153)Sm-EDTMP was repeated after 3 months in the presence of bisphosphonates (zoledronic acid every 4 weeks, first administration 1 week after (153)Sm-EDTMP administration). The retained activity in bone was evaluated 20 h after application using whole-body scintigraphy (acquisition 15 cm/min). RESULTS: Mean patient age was 69 ± 4.8 years (range 57-77 years). Mean PSA level at study entry was 18.2 ± 21.0 ng/ml. (153)Sm-EDTMP uptake ranged from 36.3 to 75.3% (mean 55.1 ± 10.9%) before bisphosphonate administration and 35.6 to 73.3% (mean 55.2 ± 10.4%) after bisphosphonate administration. No significant intra-individual difference with or without bisphosphonate treatment was observed (P = 0.647). CONCLUSIONS:Bisphosphonate treatment does not affect (153)Sm-EDTMP bone uptake in patients with castration-resistant metastatic prostate cancer. Thus, bisphosphonate treatment can be continued safely during samarium therapy.
Authors: Oliver Sartor; Robert H Reid; Peter J Hoskin; Donald P Quick; Peter J Ell; Robert E Coleman; Jon A Kotler; Leonard M Freeman; Pierre Olivier Journal: Urology Date: 2004-05 Impact factor: 2.649
Authors: M Aapro; P A Abrahamsson; J J Body; R E Coleman; R Colomer; L Costa; L Crinò; L Dirix; M Gnant; J Gralow; P Hadji; G N Hortobagyi; W Jonat; A Lipton; A Monnier; A H G Paterson; R Rizzoli; F Saad; B Thürlimann Journal: Ann Oncol Date: 2007-09-28 Impact factor: 32.976
Authors: Howard I Scher; Susan Halabi; Ian Tannock; Michael Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia Higano; Glenn J Bubley; Robert Dreicer; Daniel Petrylak; Philip Kantoff; Ethan Basch; William Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain Journal: J Clin Oncol Date: 2008-03-01 Impact factor: 44.544